Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective obesity ...
A single type of chemical structure that shows up again and again in modern medicine is the amide bond that links a carbonyl ...
From the spice rack to the lab bench, emerging proteomic insights reveal how hidden peptide fragments in everyday spices may ...
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and ...
The Tonks lab studied PTP1B inhibition in a mouse model of Alzheimer’s disease. When PTP1B was deleted, as shown in the bottom row, the brain’s immune cells (green) were better at engulfing harmful ...
PITTSBURGH - A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective ...
Cartilage is the body’s most stubborn tissue. Once it wears away, it’s usually gone for good. This biological dead-end is the ...
The immune system must maintain a delicate balance to defend against harmful threats while avoiding excessive inflammation.
By selectively blocking the ATAC complex via its unique YEATS2 subunit, a new inhibitor turns off tumor-promoting genes, ...
Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results